14 completed. 14 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes infusions - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-04-01 | 2024-06-25 |
| Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Benralizumab - Solid Tumor, Solid Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 51 | 2020-09-16 | 2026-06-01 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant Tacrolimus, Methotrexate, Tocilizumab - Hematologic Malignancy | Phase 2 | Completed | Medical College of Wisconsin | 29 | 2018-11-06 | 2023-04-19 |
| Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Isavuconazole - Hematologic Malignancy, Myeloproliferative Disorder | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 99 | 2017-05-04 | 2025-05-16 |
| A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) Duvelisib - Hematologic Malignancy | Phase 2 | Completed | SecuraBio | 19 | 2016-04-01 | 2023-09-11 |
| Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant Transplantation of cord blood expanded with UM171 - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Maisonneuve-Rosemont Hospital | 25 | 2015-12-16 | 2019-08-05 |
| Phase II Maraviroc for GVHD Prevention Maraviroc 300 mg - Hematologic Malignancy | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 37 | 2013-02-01 | 2021-01-11 |
| Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®) - Hematologic Malignancy | Phase 2 | Completed | Nantes University Hospital | 50 | 2012-04-01 | 2026-09-14 |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide - Hematologic Malignancy | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 25 | 2010-05-01 | 2025-04-30 |
| Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies haplo/cord transplant - Hematologic Malignancy, Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Completed | Joanne Kurtzberg, MD | 3 | 2007-08-01 | 2015-04-03 |
| Mindfulness Meditation in Bone Marrow Transplantation Mindfulness training, Nurse education - Hematologic Malignancy, Bone Marrow Transplantation | Phase 2 / Phase 3 | Completed | Emory University | 241 | 2005-04-01 | 2013-11-28 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases ANTI-CD45, CAMPATH-1H, FK506 - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 24 | 2002-11-01 | 2012-06-29 |
Hematologic Neoplasms (14) · Anemia, Aplastic (2) · Leukemia (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Bone Marrow Diseases (3) · Neoplasms by Histologic Type (3) · Anemia (2) · Blood Protein Disorders (2) · Bone Marrow Failure Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2)
Tacrolimus (3) · Whole-Body Irradiation (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Alemtuzumab (1) · Anti-Bacterial Agents (1) · Antiemetics (1) · Antifungal Agents (1) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclophosphamide (1) · Electrocardiography (1) · Maraviroc (1) · Methotrexate (1) · Mycophenolic Acid (1) · RNA, Messenger (1)
Memorial Sloan Kettering Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Ain Shams University (1) · Baylor College of Medicine (1) · Emory University (1) · Joanne Kurtzberg, MD (1) · Maisonneuve-Rosemont Hospital (1) · Medical College of Wisconsin (1) · Nantes University Hospital (1) · National Cancer Institute (NCI) (1) · SecuraBio (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · St. Petersburg State Pavlov Medical University (1)
United States (10) · Canada (1) · Egypt (1) · France (1) · Italy (1) · Russia (1)
Alina Markova, MD (1) · David Porter, MD (1) · Dolores Grosso, DNP, CRNP (1) · James Gulley, M.D. (1) · Joanne Kurtzberg, MD (1) · Malcolm K Brenner, MD (1) · Manal H Elsayed, MD (1) · Neal Flomenberg, MD (1) · Sandra Cohen, MD (1) · Susan Bauer-Wu, PhD (1) · William R Drobyski, MD (1)
PMID 31704264, PMID 33022376, PMID 36028757, PMID 36106394, PMID 37467030, PMID 37925363, PMID 39293082, PMID 39706761
K08HL143189 (1), P30CA008748 (1)